β Blockers in heart failure: A comparison of a vasodilating β blocker with metoprolol

Heart

Volumn 79, Issue 1, 1998, Pages 86-92

  Sanderson, J E ^a   Chan, S K W ^a   Yu, C M ^a   Yeung, L Y C ^a   Chan, W M ^a   Raymond, K ^a   Chan, K W ^b   Woo, K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Dept Diagn Radiol Organ Imaging ^*

Author keywords

Celiprolol; Heart failure; Metoprolol; Blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; METOPROLOL; VASODILATOR AGENT;

ADRENERGIC RECEPTOR BLOCKING; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASODILATATION;

EID: 0031979005     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.79.1.86     Document Type: Article

References (36)

1. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-43.
2. Leinbach WN, Wallin BG, Victor RG, Aylward PB, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-19.
3. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984;311:819-23.
4. Van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with pheochromocytoma. N Engl J Med 1966;274:1102-8.
5. Podrid PJ, Fuchs T, Candinas R. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation 1990;82(suppl I):103-13.
6. Mancia G. Sympathetic activation in congestive heart failure. Eur Heart J 1982;104(suppl A):3-11.
7. Bhambi B, Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 1991;139:1131-42.
8. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al, for the SOLVD Investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7.
9. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effects of chronic beta-receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
10. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 1994; 23:814-21.
11. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
12. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
13. Australia New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-18.
14. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity in patients with chronic heart failure. N Engl J Med 1996;334: 1349-55.
15. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
16. Yamakawa H, Takeuchi M, Takaoka H, Hata K, Mori M, Yokoyama M. Negative chronotropic effect of β-blockade therapy reduces myocardial oxygen expenditure for non-mechanical work. Circulation 1996;94:340-5.
17. Eichhorn E, Bedotto J, Malloy C, Hatfield B, Deitchman D, Brown M, et al. Effect of β-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile and diastolic performance with bucindolol. Circulation 1990;82:473-83.
18. Pfeffer MA, Stevenson LW. β-Adrenergic blockers and survival in heart failure. N Engl J Med 1996;334:1396-97.
19. Ikram H, Fitzpatrick D, Crozier I. Therapeutic controversies with use of beta-adrenoreceptor blockade in heart failure. Am J Cardiol 1993;71:54-60C.
20. Sanderson JE, Chan WWM, Hung YT, Chan SKW, Shum IOL, Raymond K, et al. Effect of low dose blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating blocker. Br Heart J 1995;74: 502-7.
21. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire. Heart Failure 1987;1:198-209.
22. Yusuf S, Tsuyuki R. Using exercise endpoints in heart failure trials: design considerations. Eur Heart J 1996;17:4-6.
23. Nishimura RA, Tajik AJ. Quantitative hemodynamics by Doppler echocardiography: a noninvasive alternative to cardiac catheterization. Prog Cardiovasc Dis 1994;36:309-42.
24. Yamamoto K, Redfield MM, Nishimura RA. Analysis of left ventricular diastolic function. Heart 1996;75(suppl 2):27-35.
25. Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996;27:1753-60.
26. Yu CM, Sanderson JE, Shum IOL, Chan S, Yeung LYC, Hung YT, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure - higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996;17:1694-702.
27. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
28. Prichard BNC. β-Blocking agents with vasodilating action. J Cardiovasc Pharmacol 1992;19(suppl 1).
29. Norris RJ. Antihypertensive therapy with celiprolol: a new cardioselective beta blocker. Am J Cardiol 1988;61:14-22C.
30. Dunn CJ, Spencer CM. Celiprolol an evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drugs Aging 1995;7:394-411.
31. Hall JA, Ferro A, Dickerson JEC, Brown MJ. β Adrenoreceptor subtype cross regulation in the human heart. Br Heart J 1993;69:332-7.
32. Yu CM, Sanderson JE, Chan S, Yeung L, Hung YT, Woo KS. Right ventricular diastolic dysfunction in heart failure. Circulation 1996;93:1509-14.
33. Andersson B, Caidahl K, di Lenarda A, Warren SE, Gross F, Waldenström A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic β-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996;94:673-82.
34. Eichhorm EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 1996; 94:2285-96.
35. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al, for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors. N Engl J Med 1993;329:1-7.
36. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al, for the SOLVD Investigators, Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 1993;270: 1702-7.